×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 4: INTERCHANGEABILITY & SWITCHING – WHERE DOES THE JOURNEY GO?
Session Chair(s)
Sabine Atzor, MPharm, RPh
Head of EU Regulatory Policies
F. Hoffmann-La Roche Ltd, Switzerland
Elena Wolff-Holz, MD, PhD
Chair, Biosimilar Medicinal Products Working Party (BMWP) of CHMP; Assessor
Paul-Ehrlich Institut, Germany
Speaker(s)
Interchangeability - A fifth hurdle for access to US market?
Paul Chamberlain
NDA Advisory Board, United Kingdom
Biopharmaceuticals & Immunogenicity Expert
Experiences in Practice - Outcome and learnings of a switching study in Norway
Guro Løvik Goll
Diakonhjemmet Hospital, Norway
Current situation in the EU – Evaluation and perspectives
Jaap Venema, PhD, PMP
Abbvie, United States
Therapeutic Area Lead Biotherapeutics, Global Medical Affairs
Current situation in the EU – Evaluation and perspectives
Suzette Kox, MPharm
Medicines for Europe, Belgium
Senior Director International-Biosimilars Medicines Group
Have an account?